Tiller, J., Otlowski, M. & Lacaze, P. Should Australia ban the use of genetic test results in life insurance? Front. Public Health 5, 330 (2017).
Article PubMed PubMed Central Google Scholar
Joly, Y., Dupras, C., Pinkesz, M., Tovino, S. A. & Rothstein, M. A. Looking beyond GINA: policy approaches to address genetic discrimination. Annu. Rev. Genom. Hum. Genet. 21, 491–507 (2020).
Otlowski, M., Taylor, S. & Bombard, Y. Genetic discrimination: international perspectives. Annu. Rev. Genom. Hum. Genet. 13, 433–454 (2012).
Green, R. C., Lautenbach, D. & McGuire, A. L. GINA, genetic discrimination, and genomic medicine. N. Engl. J. Med. 372, 397–399 (2015).
Article CAS PubMed Google Scholar
Tiller, J. et al. Genetic discrimination by Australian insurance companies: a survey of consumer experiences. Eur. J. Hum. Genet. 28, 108–113 (2020).
Joly, Y., Ngueng Feze, I. & Simard, J. Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med. 11, 25 (2013).
Article PubMed PubMed Central Google Scholar
Wauters, A. & Van Hoyweghen, I. Global trends on fears and concerns of genetic discrimination: a systematic literature review. J. Hum. Genet. 61, 275–282 (2016).
Article CAS PubMed Google Scholar
Fraser, H. et al. Genetic discrimination by insurance companies in Aotearoa New Zealand: experiences and views of health professionals. N. Z. Med. J. 136, 32–52 (2023).
Tiller, J. et al. Community concerns about genetic discrimination in life insurance persist in Australia: a survey of consumers offered genetic testing. Eur. J. Hum. Genet. (2023).
Keogh, L. A. et al. Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining. J. Behav. Med. 40, 583–594 (2017).
Article PubMed PubMed Central Google Scholar
Keogh, L. A. et al. Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? Med. J. Aust. 191, 255 (2009).
Huizenga, C. R. et al. Evolving perspectives on genetic discrimination in health insurance among health care providers. Fam. Cancer 9, 253–260 (2010).
Prince, A. E. R., Uhlmann, W. R., Suter, S. M. & Scherer, A. M. Genetic testing and insurance implications: surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA). Risk Manag Insur Rev. 24, 341–365 (2021).
Article PubMed PubMed Central Google Scholar
Yanes, T. et al. Australian researcher’s perspectives on the Australian industry-led moratorium on genetic tests in life insurance. Am. J. Med. Genet. Part A. https://doi.org/10.1002/ajmg.a.63565.
Choi, S. W., Mak, T. S.-H. & O’Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759–2772 (2020).
Article CAS PubMed PubMed Central Google Scholar
Wand, H. et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature 591, 211–219 (2021).
Article CAS PubMed PubMed Central Google Scholar
Yanes, T., McInerney-Leo, A., Law, M. & Cummings, S. The emerging field of polygenic risk scores and perspective for use in clinical care. Hum. Mol. Genet. 29, R165–R176 (2020).
Article CAS PubMed Google Scholar
Lewis, A. C. F. & Green, R. C. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Med. 13, 14 (2021).
Article PubMed PubMed Central Google Scholar
Lambert, S. A., Abraham, G. & Inouye, M. Towards clinical utility of polygenic risk scores. Hum. Mol. Genet. 28, R133–r42 (2019).
Article CAS PubMed Google Scholar
Adeyemo, A. et al. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat. Med. 27, 1876–1884 (2021).
Yanes, T., Young, M.-A., Meiser, B. & James, P. A. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field. Breast Cancer Res. 22, 21 (2020).
Article PubMed PubMed Central Google Scholar
Vassy, J. L. et al. Perceived benefits and barriers to implementing precision preventive care: results of a national physician survey. Eur. J. Hum. Genet. 31, 1309–1316 (2023).
Linnér, R. K. & Koellinger, P. D. Genetic risk scores in life insurance underwriting. J. Health Econ. 81, 102556 (2021).
Venning, B., Saya, S., De Abreu Lourenco, R., Street, D. J. & Emery, J. D. Preferences for a polygenic test to estimate cancer risk in a general Australian population. Genet. Med. 24, 2144–2154 (2022).
Article CAS PubMed Google Scholar
HM Government and Association of British Insurers. Code on Genetics and Insurance London: HM Government; [cited HM Government. Available from: https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-testing-and-insurance-final.pdf. (2018).
Financial Services Council. FSC Standard No. 11: Moratorium on Genetic Tests in Life Insurance 2019 [updated 21 June Available from: https://www.fsc.org.au/resources-category/standard/1779-standard-11-moratorium-on-genetic-tests-in-life-insurance/file. (2019).
Genetic Non-Discrimination Act, SC 2017, c.3. [Available from: https://laws-lois.justice.gc.ca/eng/acts/G-2.5/index.html. (2017).
Genetic Information Nondiscrimination Act of 2008, Pub L 110-233, 122 Stat 881 [Available from: https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008 (2008).
Kim, H. et al. Genetic discrimination: introducing the Asian perspective to the debate. npj Genom. Med. 6, 54 (2021).
Article PubMed PubMed Central Google Scholar
Treasury Department. Press Confernce: Release of consultation paper on treatment of genetic testing information for life insurance [Available from: https://ministers.treasury.gov.au/ministers/stephen-jones-2022/transcripts/press-conference-mural-hall-parliament-house-canberra (2024).
Use of genetic testing results in life insurance underwriting. In: Department T, editor. Canberra (2023).
Wand, H. et al. Clinical genetic counseling and translation considerations for polygenic scores in personalized risk assessments: a practice resource from the national society of genetic counselors. J. Genet. Counsel. 32, 558–575 (2023).
Martin, A. R., Daly, M. J., Robinson, E. B., Hyman, S. E. & Neale, B. M. Predicting polygenic risk of psychiatric disorders. Biol. Psychiatry 86, 97–109 (2019).
Kumuthini, J. et al. The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review. Hum. Genet. 141, 1697–1704 (2022).
Article PubMed PubMed Central Google Scholar
Peck, L., Borle, K., Folkersen, L. & Austin, J. Why do people seek out polygenic risk scores for complex disorders, and how do they understand and react to results? Eur. J. Hum. Genet. (2021).
Gray, S. W. et al. Personal genomic testing for cancer risk: results from the impact of personal genomics study. J. Clin. Oncol. 35, 636–644 (2017).
Widén, E. et al. How communicating polygenic and clinical risk for atherosclerotic cardiovascular disease impacts health behavior: an observational follow-up study. Circ. Genom. Precis. Med. Circgen121003459 (2022).
Timms, M. Polygenic risk scores and what it means for the genetic testing moratorium [Available from: https://www.actuaries.digital/2022/07/08/polygenic-risk-scores-and-what-it-means-for-the-genetic-testing-moratorium/(2022).
Vukcevic, D. & Chen, J. Advances in genetics and their impact on life insurance. Actuaries Institute [Available from https://www.actuaries.asn.au/Library/Events/FSF/2018/VukcevicChenPaper.pdf (2018).
Ganna, A. et al. Genetic determinants of mortality. Can findings from genome-wide association studies explain variation in human mortality? Hum. Genet. 132, 553–561 (2013).
Meisner, A. et al. Combined utility of 25 disease and risk factor polygenic risk scores for stratifying risk of all-cause mortality. Am. J. Hum. Genet. 107, 418–431 (2020).
Article CAS PubMed PubMed Central Google Scholar
Joly, Y. et al. Establishing the International genetic discrimination observatory. Nat. Genet. 52, 466–468 (2020).
Article CAS PubMed Google Scholar
Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020).
National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic [Version 1.2023:[Available from: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503 ‘15.11.22’[15.11.22]. (2022).
eviQ Cancer Treatments. Genetic Testing for Heritable Mutations in the BRCA1 and BRCA2 Genes [Available from: https://www.eviq.org.au/cancer-genetics/adult/genetic-testing-for-heritable-pathogenic-variants/620-brca1-and-brca2-genetic-testing (2021).
National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. (2019).
Hüls, A. et al. Polygenic risk for obesity and its interaction with lifestyle and sociodemographic factors in European children and adolescents. Int. J. Obes. 45, 1321–1330 (2021).
Newson, A. J., Tiller, J., Keogh, L. A., Otlowski, M. & Lacaze, P. Genetics and Insurance in Australia: concerns around a self-regulated industry. Public Health Genom. 20, 247–256 (2017).
Young, M. A. et al. Human genetics society of Australasia position statement: use of polygenic scores in clinical practice and population health. Twin Res. Hum. Genet 26, 40–48 (2023).
O’Sullivan, J. W. et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American heart association. Circulation 146, e93–e118 (2022).
Comments (0)